220 related articles for article (PubMed ID: 18275497)
1. Increased levels of serum matrix metalloproteinase-3 in haemodialysis patients with dialysis-related amyloidosis.
Naganuma T; Sugimura K; Uchida J; Tashiro K; Yoshimura R; Takemoto Y; Nakatani T
Nephrology (Carlton); 2008 Apr; 13(2):104-8. PubMed ID: 18275497
[TBL] [Abstract][Full Text] [Related]
2. Serum beta2-microglobulin level is a significant predictor of mortality in maintenance haemodialysis patients.
Okuno S; Ishimura E; Kohno K; Fujino-Katoh Y; Maeno Y; Yamakawa T; Inaba M; Nishizawa Y
Nephrol Dial Transplant; 2009 Feb; 24(2):571-7. PubMed ID: 18799606
[TBL] [Abstract][Full Text] [Related]
3. Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients.
Huang CY; Wu TC; Lin WT; Leu HB; Lin CP; Lin SJ; Chen JW
Eur J Clin Invest; 2006 Feb; 36(2):76-84. PubMed ID: 16436088
[TBL] [Abstract][Full Text] [Related]
4. Serum matrix metalloproteinase-3 in hemodialysis patients with dialysis-related amyloidosis.
Ishizaki M; Matsunaga T; Adachi K; Miyashita E
Hemodial Int; 2004 Jul; 8(3):219-25. PubMed ID: 19379421
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinases MMP-3 and MMP-1 levels in sera and synovial fluids in patients with rheumatoid arthritis and osteoarthritis.
Mahmoud RK; El-Ansary AK; El-Eishi HH; Kamal HM; El-Saeed NH
Ital J Biochem; 2005; 54(3-4):248-57. PubMed ID: 16688934
[TBL] [Abstract][Full Text] [Related]
6. Serum matrix metalloproteinase-3 in systemic sclerosis.
Jinnin M; Ihn H; Asano Y; Yamane K; Yazawa N; Tamaki K
Arch Dermatol Res; 2004 Jun; 296(1):25-9. PubMed ID: 15095096
[TBL] [Abstract][Full Text] [Related]
7. [Mediators of amyloidogenesis and cytokines in dialysis-related amyloidosis].
Rysavá R; Merta M; Tesar V; Lachmanová J; Sulková S; Bláha J
Cas Lek Cesk; 2002 Apr; 141(8):244-7. PubMed ID: 12038073
[TBL] [Abstract][Full Text] [Related]
8. Relationship of serum cystatin C with C-reactive protein and apolipoprotein A1 in patients on hemodialysis.
Samouilidou EC; Grapsa E
Ren Fail; 2008; 30(7):711-5. PubMed ID: 18704820
[TBL] [Abstract][Full Text] [Related]
9. A circulating beta 2-microglobulin intermediate in hemodialysis patients.
Uji Y; Motomiya Y; Ando Y
Nephron Clin Pract; 2009; 111(3):c173-81. PubMed ID: 19194107
[TBL] [Abstract][Full Text] [Related]
10. Relative importance of residual renal function and convection in determining beta-2-microglobulin levels in high-flux haemodialysis and on-line haemodiafiltration.
Fry AC; Singh DK; Chandna SM; Farrington K
Blood Purif; 2007; 25(3):295-302. PubMed ID: 17622712
[TBL] [Abstract][Full Text] [Related]
11. Effect of matrix metalloproteinase-3 functional SNP on serum matrix metalloproteinase-3 level and outcome measures in Japanese RA patients.
Tsukahara S; Shinozaki M; Ikari K; Mochizuki T; Inoue E; Tomatsu T; Hara M; Yamanaka H; Kamatani N; Momohara S
Rheumatology (Oxford); 2008 Jan; 47(1):41-4. PubMed ID: 18077489
[TBL] [Abstract][Full Text] [Related]
12. Serum alpha 2-macroglobulin in haemodialysis patients: baseline and kinetic studies.
Argilés A; Kerr PG; Mourad G; Mion CM; Atkins RC
Nephrol Dial Transplant; 1993; 8(10):1118-23. PubMed ID: 7505905
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphisms are associated with mortality in haemodialysis patients.
Cozzolino M; Biondi ML; Galassi A; Turri O; Brancaccio D; Gallieni M
Nephrol Dial Transplant; 2009 Jul; 24(7):2207-12. PubMed ID: 19221176
[TBL] [Abstract][Full Text] [Related]
14. Salivary beta2-microglobulin analysis in chronic kidney disease and hemodialyzed patients.
Michelis R; Sela S; Ben-Zvi I; Nagler RM
Blood Purif; 2007; 25(5-6):505-9. PubMed ID: 18187941
[TBL] [Abstract][Full Text] [Related]
15. Impact of advanced dialysis technology on the prevalence of dialysis-related amyloidosis in long-term maintenance dialysis patients.
Schiffl H
Hemodial Int; 2014 Jan; 18(1):136-41. PubMed ID: 23718290
[TBL] [Abstract][Full Text] [Related]
16. The potential of matrix metalloproteinase-2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis--a multicentre study in Japan.
Hirahara I; Inoue M; Okuda K; Ando Y; Muto S; Kusano E
Nephrol Dial Transplant; 2007 Feb; 22(2):560-7. PubMed ID: 17035369
[TBL] [Abstract][Full Text] [Related]
17. Beta2-microglobulin amyloidosis in hemodialysis and peritoneal dialysis patients.
Dervisoglu E; Anik Y; Erdogan S; Akansel G; Yilmaz A
Ther Apher Dial; 2008 Aug; 12(4):306-10. PubMed ID: 18789118
[TBL] [Abstract][Full Text] [Related]
18. Serum and cellular interleukin-6 in haemodialysis patients: relationship with energy expenditure.
Kamimura MA; Draibe SA; Dalboni MA; Cendoroglo M; Avesani CM; Manfredi SR; Canziani ME; Cuppari L
Nephrol Dial Transplant; 2007 Mar; 22(3):839-44. PubMed ID: 17205966
[TBL] [Abstract][Full Text] [Related]
19. [Clinical significance of MMP-3 in patients with rheumatoid arthritis: comparison with other inflammatory markers(IL-6, IL-8)].
Hamakawa H; Takemura M; Sato M; Shinohe R; Koishi H; Furuta N; Ohta H; Koike N; Iwamoto N; Yamada Y; Wada H; Saito K; Seishima M
Rinsho Byori; 2003 Jan; 51(1):13-8. PubMed ID: 12652686
[TBL] [Abstract][Full Text] [Related]
20. Uraemic itching: do polymethylmethacrylate dialysis membranes play a role?
Aucella F; Vigilante M; Gesuete A; Maruccio G; Specchio A; Gesualdo L
Nephrol Dial Transplant; 2007 Jul; 22 Suppl 5():v8-12. PubMed ID: 17586845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
